EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Citius Oncology, Inc. (CTOR) fair value: what the stock is really worth

We calculate from audited financials what Citius Oncology, Inc. is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.

Valuation from Jul 24, 2026. With the latest figures (losses, negative cash flow), a fair value can no longer be calculated.
  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · US · ISIN US17331Y1091

CO Citius Oncology, Inc. logo Thin data Jul 24, 2026

Citius Oncology, Inc.

CTOR · US

Weakest SetupStrongly overvalued and low quality.

!Fair value $0.3200 · Strongly overvalued (−68%)
!Quality 29/100
!negative free cash flow
!Trails peers (1/7)
!Narrow moat 5/100
!Evidence only low, so the estimate is less certain
Watch Citius Oncology, Inc. for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$40.50 $0.4930 Fair Value $0.3200 Aug 2024 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 24, 2026.

How to read this chart

25‑month range $0.4930 – $40.50 · fair‑value band $0.2400 – $0.4800 · the $1.01 price screens above the $0.3200 fair value. Dashed = 300-day average. As of Jul 24, 2026.

Follow Citius Oncology in your weekly email

Every Wednesday you see whether Citius Oncology is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma.

Show more

Citius Oncology, Inc. focuses on the development and commercialization of innovative targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed or refractory cutaneous T-cell lymphoma, a rare form of non-Hodgkin lymphoma. The company is headquartered in Cranford, New Jersey. Citius Oncology, Inc. is a subsidiary of Leonard-Meron Biosciences, Inc.

Stock analysis

Citius Oncology, Inc. (CTOR) currently trades at $1.01, while our model-based Fair Value estimate is $0.3200, implying the stock looks roughly 215.7% overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 91/100, which puts the evidence level at low.

Scenario range: $0.2400 (bear) to $0.4800 (bull), the price of $1.01 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 29/100 (below-average quality), in the Healthcare sector.

Citius Oncology, Inc. reported revenue of $0 in FY2025 versus $0 in FY2022. Reported net income was −$24.8M in FY2025.

Key figures

Market cap $74.0M · P/S ratio 11.1 · EPS (TTM) $−0.4800 · Return on equity −120% · Return on assets (EBIT) −24.0% · Operating margin −1,716% · Revenue (TTM) $5.6M · Free cash flow −$5.5M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 50% below its 52-week high and 105% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −68%, CTOR screens richer than that median.

Fair Value models

Bear $0.2400 Fair Value $0.3200 Bull $0.4800
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) $0.2400 $0.3200 $0.4800 51
All 1 models by family
Asset-Based
NCAV (Graham) $0.2400 $0.3200 $0.4800 51

Open the full fair value analysis →

Notify me when CTOR reaches fair value

Put CTOR on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 29/100

Of which business quality 30 · Market factors (momentum, volatility) 34

Profitability 0
Margins and returns on capital today
Quality Growth 53
Are margins and returns improving?
Cashflow 0
Earnings quality: real cash, not paper profit
Fin. Strength 44
Balance sheet, leverage, solvency risk
Investment 32
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 67
Price trend over the last 3–12 months (market factor)
52W Momentum 17
Distance to the 52-week high (market factor)
Net Issuance 78
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

CTOR screens 216% overvalued. Compare with Merck KGaA →

Compare Citius Oncology, Inc. with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Drug Manufacturers - Specialty & Generic · 630 stocks

Beats the industry median on 0/5 measures
Overall it trails its industry peers.
Valuation
Quality Score 30 · Bottom 25%
Fair Value upside −68% · Bottom 25%
Profitability
Return on assets −28% · Bottom 25%
Growth and dividend
Revenue growth 0% · Below median

Valuation Multiplesvs Drug Manufacturers - Specialty & Generic median · lower = cheaper

P/B 1.65× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (TTM) 13.19× · Priciest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Merck KGaA MRK €133.15 €108.70 −18%
Takeda Pharmaceutical Company TAK $18.95 $11.29 −40%
Jiangsu Hengrui Pharmaceuticals Co 600276 ¥45.58 ¥50.14 +10%
Sun Pharmaceutical Industries Limited SUNPHARMA ₹1,865 ₹1,979 +6%
Galderma Group GALD CHF 163.80 CHF 109.88 −33%
Haleon plc HLN $9.25 $8.50 −8%
Teva Pharmaceutical Industries Limited TEVA $39.52 $20.75 −47%
Sandoz Group SDZ CHF 70.76 CHF 40.16 −43%
Zoetis Inc ZTS $72.86 $108.48 +49%
Hansoh Pharmaceutical Group 3692 HK$35.34 HK$38.87 +10%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Citius Oncology, Inc. · Fair Value
$0.3200 −216%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Citius Oncology, Inc. Fair Value". https://www.fairvalue-calculator.com/stock/CTOR

Frequently asked questions

Is Citius Oncology, Inc. (CTOR) overvalued or undervalued?
As of Jul 24, 2026, our model estimates a fair value of $0.3200 versus a price of $1.01, about −68% upside (overvalued).
What is the fair value of CTOR?
Our model-based fair value for Citius Oncology, Inc. is $0.3200 (as of Jul 24, 2026), built from audited fundamentals. The current price: $1.01.
What is the quality score of CTOR?
Citius Oncology, Inc. has a Quality Score of 29/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Citius Oncology, Inc. (CTOR)?
Our model-based price target is the fair value of $0.3200 (as of Jul 24, 2026) from 1 valuation models. Cautious scenario $0.2400, optimistic scenario $0.4800. It is a calculation from audited fundamentals, not an analyst target.
What is the Citius Oncology, Inc. stock forecast for 2026?
Our models put fair value at $0.3200, about −68% upside versus a price of $1.01 (overvalued). Cautious scenario $0.2400, optimistic scenario $0.4800. The calculation is refreshed regularly with new filings.
What is the revenue of Citius Oncology, Inc. (CTOR)?
Citius Oncology, Inc. reported trailing-twelve-month revenue of about $5.6M (latest available figure, as of Jul 24, 2026).
What is the intrinsic value of Citius Oncology, Inc. (CTOR)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Citius Oncology, Inc. it is $0.3200 per share (as of Jul 24, 2026), against a price of $1.01. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Citius Oncology, Inc. stock overvalued or undervalued in 2026?
As of Jul 24, 2026, CTOR trades above its calculated fair value: price $1.01, fair value $0.3200, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of CTOR?
No. The price is what the market pays today ($1.01); the fair value is what the company's own numbers justify ($0.3200). For Citius Oncology, Inc. the two are $0.6900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Citius Oncology, Inc. worth?
The market values Citius Oncology, Inc. at about $74.0M (market capitalisation, as of Jul 24, 2026). Per share that is $1.01; our models calculate a fair value of $0.3200 per share.
What do the bullish and bearish scenarios say about CTOR?
Our models span a range for Citius Oncology, Inc.: cautious scenario $0.2400, base $0.3200, optimistic $0.4800 per share (as of Jul 24, 2026, price $1.01). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Citius Oncology, Inc. (CTOR)?
Balance-sheet figures for Citius Oncology, Inc. (as of Jul 24, 2026): return on equity −119.9%. They feed the Quality Score of 29/100, which measures business quality independently of the share price.
How far is CTOR from its 52-week high?
Citius Oncology, Inc. trades at $1.01, about 50% below its 52-week high of $2.03 and 105% above the low of $0.4930 (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of $0.3200 is for.
Which stocks are comparable to Citius Oncology, Inc.?
From the same area (Healthcare) we also value Merck KGaA, Takeda Pharmaceutical Company, Jiangsu Hengrui Pharmaceuticals Co, Sun Pharmaceutical Industries Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Citius Oncology, Inc. stock attractive at the current price?
The data as of Jul 24, 2026: price $1.01, calculated fair value $0.3200 (−68%), Quality Score 29/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of CTOR calculated?
We run Citius Oncology, Inc. through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.3200, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.2 % above its aggregate fair value. Citius Oncology, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Citius Oncology, Inc. (CTOR)?
The closing price on Sep 23, 2026 was $1.01. Our model-based fair value is $0.3200, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Citius Oncology, Inc. right now?
The price sits above even our optimistic bull case ($0.4800). The favourable scenario is already priced in. Weak quality (29/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range ($0.2400 to $0.4800) leaves room in how you read the outcome.

Key figures of Citius Oncology, Inc.

How large is the market capitalisation of Citius Oncology, Inc. (CTOR)?
The market capitalisation of Citius Oncology, Inc. is $74.0M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Citius Oncology, Inc. (CTOR)?
The price-to-sales ratio of Citius Oncology, Inc. is 11.1 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Citius Oncology, Inc. (CTOR)?
Earnings per share at Citius Oncology, Inc. are $−0.4800. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Citius Oncology, Inc. (CTOR)?
The return on equity (ROE) of Citius Oncology, Inc. is −120% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Citius Oncology, Inc. (CTOR)?
On an EBIT basis the return on assets of Citius Oncology, Inc. is −24.0% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Citius Oncology, Inc. (CTOR)?
The operating margin of Citius Oncology, Inc. is −1,716% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How much free cash flow does Citius Oncology, Inc. (CTOR) generate?
The free cash flow of Citius Oncology, Inc. is −$5.5M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net cash does Citius Oncology, Inc. (CTOR) hold?
Citius Oncology, Inc. holds more cash than debt, $125K net (fiscal year 2025). The company holds more cash than debt, a safety cushion.
Free · no account needed

Watch Citius Oncology, Inc. in the live analysis

One click puts Citius Oncology, Inc. on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.